This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.03% per year. These returns cover a period from January 1, 1988 through July 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Harrow (HROW) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of 48% and 14.40%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
Harrow (HROW) Is a Great Choice for 'Trend' Investors, Here's Why
by Zacks Equity Research
Harrow (HROW) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Harrow (HROW) Soars 12.9%: Is Further Upside Left in the Stock?
by Zacks Equity Research
Harrow (HROW) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
VYNE Therapeutics Inc. (VYNE) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
VYNE Therapeutics (VYNE) delivered earnings and revenue surprises of 37.50% and 2%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
New Strong Sell Stocks for November 14th
by Zacks Equity Research
AKZOY, GTX and HROW have been added to the Zacks Rank #5 (Strong Sell) List on November 14, 2023.
Establishment Labs Holdings Inc. (ESTA) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of 4.41% and 2.78%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Harrow (HROW): Can Its 17.8% Jump Turn into More Strength?
by Zacks Equity Research
Harrow (HROW) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Harrow Health (HROW) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Harrow Health (HROW) closed at $18.72 in the latest trading session, marking a +1.99% move from the prior day.
Harrow Health (HROW) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Harrow Health (HROW) closed the most recent trading day at $17.91, moving +0.73% from the previous trading session.
Harrow Health (HROW) Flat As Market Sinks: What You Should Know
by Zacks Equity Research
Harrow Health (HROW) closed at $18.52 in the latest trading session, marking no change from the prior day.
Harrow Health (HROW) Dips More Than Broader Markets: What You Should Know
by Zacks Equity Research
In the latest trading session, Harrow Health (HROW) closed at $18.68, marking a -1.01% move from the previous day.
Analysts Initiate Coverage: 5 Stocks for Higher Returns
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like MicroStrategy (MSTR), SPX Technologies (SPXC), Cvent (CVT), Harrow Health (HROW) and Banco (BMA).
Harrow Health (HROW) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Harrow (HROW) delivered earnings and revenue surprises of 50% and 0.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Establishment Labs Holdings Inc. (ESTA) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Establishment Labs Holdings Inc. (ESTA) delivered earnings and revenue surprises of 33.33% and 1.69%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Harrow Health (HROW) to Report Q1 Earnings: What's in the Offing?
by Zacks Equity Research
Harrow Health's (HROW) first-quarter top line is likely to have been driven by its recent product launches.
Zacks.com featured highlights Arcellx, Harrow Health, PROG, Chipotle Mexican Grill and Meta
by Zacks Equity Research
Arcellx, Harrow Health, PROG, Chipotle Mexican Grill and Meta have been highlighted in this Screen of The Week article.
5 Stocks With Recent Price Strength That Still Have Upside
by Nalak Das
Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are META, CMG, ACLX, HROW and PRG.
Use New Analyst Coverage to Find Great Momentum Stocks to Buy in May
by Benjamin Rains
One way for investors to find potentially market-beating stocks to buy in May is to search for stocks gaining analyst coverage.
Is HCA Healthcare (HCA) Outperforming Other Medical Stocks This Year?
by Zacks Equity Research
Here is how HCA Healthcare (HCA) and Harrow Health (HROW) have performed compared to their sector so far this year.
Here's Why Momentum in Harrow (HROW) Should Keep going
by Zacks Equity Research
Harrow (HROW) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.
Harrow Health (HROW) Stock Sinks As Market Gains: What You Should Know
by Zacks Equity Research
Harrow Health (HROW) closed at $25.23 in the latest trading session, marking a -0.63% move from the prior day.
Zacks.com featured highlights Harrow Health and Disc Medicine Opco
by Zacks Equity Research
Harrow Health and Disc Medicine Opco have been highlighted in this Screen of The Week article.
2 Stocks in Focus as Analysts Initiate Coverage
by Shrabana Mukherjee
Increased analyst coverage over the last few weeks might lead to solid price appreciation for stocks like Harrow Health (HROW) and Disc Medicine (IRON).
Harrow Health and CDW have been highlighted as Zacks Bull and Bear of the Day
by Zacks Equity Research
Harrow Health and CDW have been highlighted as Zacks Bull and Bear of the Day.
Bull Of The Day: Harrow Health (HROW)
by Brian Bolan
This "roll up" play is expected to post some good growth this year as well as next.